| Secondary |
| Hypertension |
28.1% |
| Drug Use For Unknown Indication |
12.5% |
| Product Used For Unknown Indication |
9.4% |
| Rheumatoid Arthritis |
9.4% |
| Accidental Exposure |
6.3% |
| Dementia |
6.3% |
| Atrial Fibrillation |
3.1% |
| Parenteral Nutrition |
3.1% |
| Sepsis |
3.1% |
| Thrombosis Prophylaxis |
3.1% |
| Cardiac Failure |
1.6% |
| Cerebrovascular Accident Prophylaxis |
1.6% |
| Diverticulitis |
1.6% |
| Hyperparathyroidism Secondary |
1.6% |
| Polyneuropathy |
1.6% |
| Prophylaxis |
1.6% |
| Renal Failure |
1.6% |
| Secondary Hypothyroidism |
1.6% |
| Supraventricular Tachycardia |
1.6% |
| Tachycardia |
1.6% |
|
| Stevens-johnson Syndrome |
18.2% |
| Ventricular Fibrillation |
18.2% |
| Accidental Drug Intake By Child |
9.1% |
| Cardiac Arrest |
9.1% |
| Orthostatic Hypotension |
9.1% |
| Pneumonia Aspiration |
9.1% |
| Urogenital Haemorrhage |
9.1% |
| Ventricular Flutter |
9.1% |
| Vomiting |
9.1% |
|
| Concomitant |
| Hypertension |
30.0% |
| Drug Use For Unknown Indication |
17.8% |
| Product Used For Unknown Indication |
7.4% |
| Hypercholesterolaemia |
4.8% |
| Diabetes Mellitus |
4.6% |
| Diarrhoea |
3.7% |
| Rheumatoid Arthritis |
3.7% |
| Prophylaxis |
3.5% |
| Chronic Myeloid Leukaemia |
3.0% |
| Acute Coronary Syndrome |
2.8% |
| Breast Cancer |
2.8% |
| Ventricular Extrasystoles |
2.4% |
| Neuroendocrine Tumour |
2.2% |
| Non-small Cell Lung Cancer |
2.0% |
| Angioedema |
1.7% |
| Atrial Fibrillation |
1.7% |
| Tongue Oedema |
1.7% |
| Coronary Artery Disease |
1.5% |
| Benign Prostatic Hyperplasia |
1.3% |
| Osteoporosis |
1.3% |
|
| Ventricular Fibrillation |
14.5% |
| Weight Decreased |
9.2% |
| Pyrexia |
7.9% |
| Renin Increased |
7.9% |
| Acute Myocardial Infarction |
5.3% |
| Respiratory Failure |
5.3% |
| Skin Toxicity |
5.3% |
| Visual Impairment |
5.3% |
| Weight Increased |
5.3% |
| Ileus Paralytic |
3.9% |
| Pulmonary Embolism |
3.9% |
| Renal Failure |
3.9% |
| Renal Impairment |
3.9% |
| Arrhythmia |
2.6% |
| Blood Pressure Increased |
2.6% |
| Death |
2.6% |
| Drug Interaction |
2.6% |
| Erysipelas |
2.6% |
| Haemorrhage |
2.6% |
| Hypertensive Crisis |
2.6% |
|
| Interacting |
| Diuretic Therapy |
50.0% |
| Hypertension |
50.0% |
|
|
